Depression - Major Depressive DisorderNCT07189689
Mental Health Mission Mood Disorder Cohort Study
An observational study of Depression - Major Depressive Disorder and Depression Bipolar, run by University of Oxford at 1 site in United Kingdom.
Trial summary
The current study aims to understand why some people with depression respond to treatment and others do not, using markers of clinical symptoms, both clinician reported outcome measures and patient reported outcome measures, demographic information, cognitive function, genetic sequence information (genomic), chemical… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Depression - Major Depressive Disorder, Depression Bipolar, Treatment Resistant Depression
- How many people
- 2,000 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Oct 2025to 31 Jan 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The current study aims to recruit adults aged 18 and over, currently residing in the UK with a diagnosis of major depressive disorder or bipolar disorder. The study will be advertised on social media and will allow people to self-refer to the study. We will also recruit via GP mail outs.
Who may be able to join
- Those aged 18 and above
- Primary clinical diagnosis of MDD or bipolar disorder based on DSM-5/ICD-11 diagnostic criteria
- Participant is willing and able to give informed consent for participation in the study
- Possesses sufficient command of the English language required to complete study requirements, as assessed by the study team
Who cannot join
- Inability to complete study activities as assessed by the study team
- Presentation requires immediate emergency treatment
- Presentation requires clinical input not available within the research clinic
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Professor Michael Browning contact
United Kingdom1 site
Clinical Research Facility, Warneford Hospital
Oxford
Alexander Lewis, +441865618152, alexander.lewis@psych.ox.ac.uk
About this study
The current study aims to understand why some people with depression respond to treatment and others do not, using markers of clinical symptoms, both clinician reported outcome measures and patient reported outcome measures, demographic information, cognitive function, genetic sequence information (genomic), chemical measures of metabolism (metabolomic), protein makeup (proteomic) and the body's natural defence system (immune/inflammatory markers) together with collections of cells that will facilitate new research to drive improvements in diagnosis and treatment of mood disorders that may be proving difficult to treat. This will allow future clinical trials within the NHS, academia and industry to drive forward new approaches and treatments.
Participants who provide consent for re-contact for future treatment trials and other research studies have the potential to benefit from this with participation in experimental studies and clinical trials associated with improved patient outcomes. Overall, the cohort will generally support greater access to research opportunities for a wider population of people.
- Conditions
- Depression - Major Depressive Disorder, Depression Bipolar, Treatment Resistant Depression
- Keywords
- Observational, Cohort, Depression, UK, Mission, Bipolar, TRD, Difficult-to-treat, Treatment resistant depression, Bipolar depression, cohort study, Observational study
- Medical subject headings
- Bipolar Disorder, Depressive Disorder, Treatment-Resistant, Depression
What is being measured
The primary outcome is the main question the study is designed to answer.
PHQ-9
Patient Health Questionnaire - 9-item Depression scale. Scores range between 0-27, with higher scores indicating worse depression.
Measured: Up to 36 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2025
- Study start1 Oct 2025 (estimated)
- Primary completion31 Jan 2028 (estimated)
- Study completion31 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Depression - Major Depressive DisorderStudies of the same condition, open and under way.
- More trials run by University of OxfordThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Oxford
- Sponsor type
- University, hospital or other
- Collaborators
- Newcastle University, University of Nottingham, University of Exeter, University of Southampton, University of Birmingham, University of Manchester, University of Liverpool, Avon and Wiltshire Mental Health Partnership NHS Trust, Cambridgeshire and Peterborough NHS Foundation Trust, University of Cambridge, Cardiff University, Cardiff and Vale University Health Board, University of Edinburgh, University of Glasgow, University College, London, Sheffield Health and Social Care NHS Foundation Trust, King's College London, Imperial College London, Oxford Health NHS FT, Cumbria, Northumberland, Tyne and Wear NHS FT, South London and Maudsley NHS FT, Nottinghamshire Healthcare NHS FT, Devon Partnership Trust, Hampshire and Isle of Wight Health NHS FT, Birmingham and Solihull Mental Health NHS Trust, Mersey Care NHS FT, NHS Lothian, NHS Greater Glasgow and Clyde, Camden & Islington NHS FT, West London NHS FT, Central and North West London NHS FT
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07189689
- Sponsor's protocol ID
- 18955
- Other IDs
- 345799
- Status last verified
- Sep 2025
- First submitted
- 31 Jul 2025
- Last updated
- 3 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 3 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mental Health Mission Mood Disorder Cohort Study
- ClinicalTrials.gov ID
- NCT07189689
- Acronym / sponsor ID
- 18955
- Conditions
- Depression - Major Depressive Disorder, Depression Bipolar, Treatment Resistant Depression
- Keywords
- Observational, Cohort, Depression, UK, Mission, Bipolar, TRD, Difficult-to-treat
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- University of OxfordUniversity, hospital or other
- Collaborators
- Newcastle University, University of Nottingham, University of Exeter, University of Southampton, University of Birmingham, University of Manchester, University of Liverpool, Avon and Wiltshire Mental Health Partnership NHS Trust, Cambridgeshire and Peterborough NHS Foundation Trust, University of Cambridge, Cardiff University, Cardiff and Vale University Health Board, University of Edinburgh, University of Glasgow, University College, London, Sheffield Health and Social Care NHS Foundation Trust, King's College London, Imperial College London, Oxford Health NHS FT, Cumbria, Northumberland, Tyne and Wear NHS FT, South London and Maudsley NHS FT, Nottinghamshire Healthcare NHS FT, Devon Partnership Trust, Hampshire and Isle of Wight Health NHS FT, Birmingham and Solihull Mental Health NHS Trust, Mersey Care NHS FT, NHS Lothian, NHS Greater Glasgow and Clyde, Camden & Islington NHS FT, West London NHS FT, Central and North West London NHS FT
- Study start
- 1 Oct 2025 (estimated)
- Primary completion
- 31 Jan 2028 (estimated)
- Study completion
- 31 Jan 2028 (estimated)
- First posted
- 24 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The current study aims to understand why some people with depression respond to treatment and others do not, using markers of clinical symptoms, both clinician reported outcome measures and patient reported outcome measures, demographic information, cognitive function, genetic sequence information (genomic), chemical measures of metabolism (metabolomic), protein makeup (proteomic) and the body's natural defence system (immune/inflammatory markers) together with collections of cells that will facilitate new research to drive improvements in diagnosis and treatment of mood disorders that may be proving difficult to treat. This will allow future clinical trials within the NHS, academia and industry to drive forward new approaches and treatments.
Participants who provide consent for re-contact for future treatment trials and other research studies have the potential to benefit from this with participation in experimental studies and clinical trials associated with improved patient outcomes. Overall, the cohort will generally support greater access to research opportunities for a wider population of people.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The current study aims to recruit adults aged 18 and over, currently residing in the UK with a diagnosis of major depressive disorder or bipolar disorder. The study will be advertised on social media and will allow people to self-refer to the study. We will also recruit via GP mail outs.
Key inclusion criteria (4 listed)
- Those aged 18 and above
- Primary clinical diagnosis of MDD or bipolar disorder based on DSM-5/ICD-11 diagnostic criteria
- Participant is willing and able to give informed consent for participation in the study
- Possesses sufficient command of the English language required to complete study requirements, as assessed by the study team
Key exclusion criteria (3 listed)
- Inability to complete study activities as assessed by the study team
- Presentation requires immediate emergency treatment
- Presentation requires clinical input not available within the research clinic
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
PHQ-9
Time frame: Up to 36 months.
Patient Health Questionnaire - 9-item Depression scale. Scores range between 0-27, with higher scores indicating worse depression.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Oct 2025.
- Individual participant dataSharing planned: Yes
Related trials for Depression - Major Depressive Disorder
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
RecruitingPhase 4
Biomarker-Guided Antidepressant Selection
Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD)
Recruiting
Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics
Major Depressive Disorder, Apathy
RecruitingObservational study
Student Precarity and Psychiatry
Depressive Disorder, Major, Generalized Anxiety Disorder
Not yet recruiting
Acute Intermittent Hypoxia Therapy for Depression
Major Depressive Disorder (MDD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Professor Michael Browning contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Depression - Major Depressive Disorder and Depression Bipolar, run by University of Oxford at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 3 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alexander Lewis (+441865618152, alexander.lewis@psych.ox.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
PHQ-9 (time frame: Up to 36 months.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Oct 2025.